Panbela Therapeutics (PBLA) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 10, 2022
Document Information [Line Items]
Entity Central Index Key	0001029125
Entity Registrant Name	Panbela Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-39468
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0543922
Entity Address, Address Line One	712 Vista Blvd #305
Entity Address, City or Town	Waconia
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55387
City Area Code	952
Local Phone Number	479-1196
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	PBLA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		13,449,117

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 7,386	$ 11,867
Prepaid expenses and other current assets	182	91
Income tax receivable	365	321
Total current assets	7,933	12,279
Deposits held for clinical trial costs	3,155	593
Total assets	11,088	12,872
Current liabilities:
Accounts payable	3,986	640
Accrued expenses	521	2,020
Total current liabilities	4,507	2,660
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of March 31, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 13,449,117 and 13,443,722 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively	13	13
Additional paid-in capital	66,561	66,227
Accumulated deficit	(59,827)	(56,161)
Accumulated comprehensive (loss) income	(166)	133
Total stockholders' equity	6,581	10,212
Total liabilities and stockholders' equity	$ 11,088	$ 12,872

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	13,449,117	13,443,722
Common stock, shares outstanding (in shares)	13,449,117	13,443,722

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
General and administrative	$ 1,796	$ 1,149
Research and development	2,208	1,099
Operating loss	(4,004)	(2,248)
Other income (expense):
Interest income	1	0
Interest expense	(3)	(3)
Other income (expense)	311	(122)
Total other income (expense)	309	(125)
Loss before income tax benefit	(3,695)	(2,373)
Income tax benefit	29	116
Net loss	(3,666)	(2,257)
Foreign currency translation adjustment	(299)	99
Comprehensive loss	$ (3,965)	$ (2,158)
Basic and diluted net loss per share (in dollars per share)	$ (0.27)	$ (0.23)
Weighted average shares outstanding - basic and diluted (in shares)	13,445,732	9,887,578

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Dec. 31, 2020	9,664,000
Balances at Dec. 31, 2020	$ 10	$ 54,848	$ (46,026)	$ (384)	$ 8,448
Vesting of restricted stock (in shares)	7,000
Vesting of restricted stock	$ 0	0	0	0	0
Stock-based compensation	0	252	0	0	252
Net loss	0	0	(2,257)	0	(2,257)
Foreign currency translation adjustment	$ 0	0	0	99	$ 99
Exercise of warrants for cash (in shares)	229,000				228,939
Exercise of warrants for cash	$ 0	1,042	0	0	$ 1,042
Exercise of warrants, cashless (in shares)	189,000
Exercise of warrants, cashless	$ 0	0	0	0	0
Balances (in shares) at Mar. 31, 2021	10,089,000
Balances at Mar. 31, 2021	$ 10	56,142	(48,283)	(285)	7,584
Balances (in shares) at Dec. 31, 2021	13,443,000
Balances at Dec. 31, 2021	$ 13	66,227	(56,161)	133	10,212
Vesting of restricted stock (in shares)	6,000
Vesting of restricted stock	$ 0	0	0	0	0
Stock-based compensation	0	334	0	0	334
Net loss	0	0	(3,666)	0	(3,666)
Foreign currency translation adjustment	$ 0	0	0	(299)	(299)
Balances (in shares) at Mar. 31, 2022	13,449,000
Balances at Mar. 31, 2022	$ 13	$ 66,561	$ (59,827)	$ (166)	$ 6,581

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (3,666)	$ (2,257)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	334	252
Changes in operating assets and liabilities:
Income tax receivable	(33)	(113)
Prepaid expenses and other current assets	(89)	100
Deposits held for clinical trial costs	(2,561)	0
Accounts payable	3,030	334
Accrued liabilities	(1,498)	(281)
Net cash used in operating activities	(4,483)	(1,965)
Cash flows from financing activities:
Proceeds from exercise of stock purchase warrants	0	1,042
Net cash provided by financing activities	0	1,042
Effect of exchange rate changes on cash	2	(1)
Net change in cash	(4,481)	(924)
Cash and cash equivalents at beginning of period	11,867	9,022
Cash and cash equivalents at end of period	7,386	8,098
Supplemental disclosure of cash flow information:
Cash paid during period for interest	$ 3	$ 3

Note 1 - Business

Note 1 - Business	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Business Nature of Business Panbela Therapeutics, Inc. and its wholly-owned subsidiary Panbela Therapeutics Pty Ltd (collectively “we,” “us,” “our,” and the “Company”) exist for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for the treatment of patients with pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP- 101,

Note 2 - Risks and Uncertaintie

Note 2 - Risks and Uncertainties	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Nature of Operations [Text Block]	2. Risks and Uncertainties The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may We have incurred losses of $59.8 million since our inception in 2011. three March 31, 2022, March 31, 2022, The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed not 2021 March 24, 2022. 101 101 4 March 2022 two 19” 19, 2020, first 2021 second 2021, 2021, first 2022, 19 19 2021, 19. no January 2022, not 19. no

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	3. Basis of Presentation We have prepared the accompanying interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 X not December 31. December 31, 2021 not 10 may not

Note 4 - Liquidity and Business

Note 4 - Liquidity and Business Plan	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	4. Liquidity and Business Plan We will need to raise additional capital to support our current business plans. We may no not On July 2, 2021, first 2021, Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for SBP- 101 101 not not There can be no

Note 5 - Summary of Significant

Note 5 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	5. Summary of Significant Accounting Policies Principles of consolidation The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties with the ongoing pandemic and control responses. Research and development costs Research and development costs include expenses incurred in the conduct of our second 1 third 101 101 We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. All material CRO contracts are terminable by us upon written notice, and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not Foreign currency translation adjustments The functional currency of Panbela Therapeutics Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Panbela Therapeutics Australia Pty Ltd, are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders’ equity. During the three March 31, 2022 2021, Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include outstanding common stock options, and warrants, have not The following table sets forth the potential shares of common stock that were not March 31, 2022 2021 Employee and non-employee stock options 2,444,136 2,385,871 Restricted stock units 5,395 4,600 Common stock issuable under common stock purchase warrants 5,109,501 5,710,190 7,559,032 8,100,661 Recently Adopted Accounting Pronouncements In August 2020, No. 2020 06, 470 20 815 40 December 15, 2021, December 31, 2022. not

Note 6 - Stockholders' Equity

Note 6 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	6. Stockholders Equity Proposed Acquisition On February 21, 2022, first Under the terms of the agreement and plan of merger, the holders of CPP’s outstanding capital stock immediately prior to the merger will receive shares of common stock of Panbela upon closing of the mergers. Panbela stockholders are expected to retain a majority of the outstanding shares of the post-merger holding company. CPP stockholders will be eligible to receive contingent payments totaling a maximum of $60 million from milestone and royalty payments associated with the potential approval and commercialization of the lead asset. The issuance of shares is subject to shareholder approval and it is expected that the mergers will be completed, if the share issuance is approved, by the end of the second 2022. Shares reserved The following shares of common stock were reserved for future issuance as of the date indicated: March 31, 2022 Stock options outstanding 2,444,136 Restricted stock units 5,395 Shares available for grant under equity incentive plan 2,019,776 Warrants outstanding 5,109,501 9,578,808

Note 7 - Stock-based Compensati

Note 7 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	7. Stock-based Compensation 2016 The Panbela Therapeutics, Inc. 2016 “2016 March 2016 May 2016. 2016 2016 no 2016 ten March 31, 2022, one 2016 2011 Our Board of Directors ceased making awards under the Panbela Therapeutics, Inc. 2011 “2011 2016 May 2016. 2011 March 31, 2022, 2011 Stock-based Compensation Expense General and administrative (“G&A”) and research and development (“R&D”) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through March 31, 2022 March 31, 2022. Stock-based compensation expense for each of the periods presented is as follows (in thousands): Three Months Ended March 31, 2022 2021 General and Administrative $ 271 $ 225 Research and Development 63 27 $ 334 $ 252 Details of options available to grant, granted, exercised, cancelled or forfeited during the three March 31, 2022 Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2022 2,463,636 $ 5.76 $ 8,821 Additional shares available to grant - - Granted - - Exercised - - Cancelled - - Forfeitures or expirations (19,500 ) 14.07 Balance at March 31, 2022 2,444,136 $ 5.76 $ 13,300 Information about stock options outstanding, vested and expected to vest as of March 31, 2022, Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $ 1.10 14,000 1.20 $ 1.100 14,000 1.20 $ 2.26 - $2.50 79,225 7.37 $ 2.310 22,000 1.95 $ 2.95 - $4.17 1,207,940 7.20 $ 3.410 856,821 6.62 $ 4.50 - $8.10 687,100 6.44 $ 6.134 609,600 6.22 $ 9.99 - $10.10 262,048 7.80 $ 9.992 156,024 7.47 $ 15.10 193,823 4.70 $ 15.100 193,823 4.70 Totals 2,444,136 7.08 $ 5.760 1,852,268 6.26

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of consolidation The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties with the ongoing pandemic and control responses.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs Research and development costs include expenses incurred in the conduct of our second 1 third 101 101 We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. All material CRO contracts are terminable by us upon written notice, and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no
Share-Based Payment Arrangement [Policy Text Block]	Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation adjustments The functional currency of Panbela Therapeutics Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Panbela Therapeutics Australia Pty Ltd, are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders’ equity. During the three March 31, 2022 2021,
Comprehensive Income, Policy [Policy Text Block]	Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation.
Earnings Per Share, Policy [Policy Text Block]	Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include outstanding common stock options, and warrants, have not The following table sets forth the potential shares of common stock that were not March 31, 2022 2021 Employee and non-employee stock options 2,444,136 2,385,871 Restricted stock units 5,395 4,600 Common stock issuable under common stock purchase warrants 5,109,501 5,710,190 7,559,032 8,100,661
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In August 2020, No. 2020 06, 470 20 815 40 December 15, 2021, December 31, 2022. not

Note 5 - Summary of Significa_2

Note 5 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	March 31, 2022 2021 Employee and non-employee stock options 2,444,136 2,385,871 Restricted stock units 5,395 4,600 Common stock issuable under common stock purchase warrants 5,109,501 5,710,190 7,559,032 8,100,661

Note 6 - Stockholders' Equity (

Note 6 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Common Stock Reserved for Future Issuance [Table Text Block]	March 31, 2022 Stock options outstanding 2,444,136 Restricted stock units 5,395 Shares available for grant under equity incentive plan 2,019,776 Warrants outstanding 5,109,501 9,578,808

Note 7 - Stock-based Compensa_2

Note 7 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2022 2021 General and Administrative $ 271 $ 225 Research and Development 63 27 $ 334 $ 252
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at January 1, 2022 2,463,636 $ 5.76 $ 8,821 Additional shares available to grant - - Granted - - Exercised - - Cancelled - - Forfeitures or expirations (19,500 ) 14.07 Balance at March 31, 2022 2,444,136 $ 5.76 $ 13,300
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $ 1.10 14,000 1.20 $ 1.100 14,000 1.20 $ 2.26 - $2.50 79,225 7.37 $ 2.310 22,000 1.95 $ 2.95 - $4.17 1,207,940 7.20 $ 3.410 856,821 6.62 $ 4.50 - $8.10 687,100 6.44 $ 6.134 609,600 6.22 $ 9.99 - $10.10 262,048 7.80 $ 9.992 156,024 7.47 $ 15.10 193,823 4.70 $ 15.100 193,823 4.70 Totals 2,444,136 7.08 $ 5.760 1,852,268 6.26

Note 2 - Risks and Uncertaint_2

Note 2 - Risks and Uncertainties (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Retained Earnings (Accumulated Deficit), Total	$ (59,827)		$ (56,161)
Net Income (Loss) Attributable to Parent, Total	(3,666)	$ (2,257)
Net Cash Provided by (Used in) Operating Activities, Total	(4,483)	(1,965)
Cash and Cash Equivalents, at Carrying Value, Total	7,386		11,867
Working Capital	3,400
Stockholders' Equity Attributable to Parent, Ending Balance	$ 6,581	$ 7,584	$ 10,212	$ 8,448

Note 4 - Liquidity and Busine_2

Note 4 - Liquidity and Business Plan (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jul. 02, 2021	Mar. 31, 2022	Mar. 31, 2021
Proceeds from Warrant Exercises		$ 0	$ 1,042
Stock Issued During Period, Shares, Exercise of Warrants for Cash (in shares)			228,939
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	3,333,334
Shares Issued, Price Per Share (in dollars per share)	$ 3
Proceeds from Issuance of Common Stock, Net	$ 9,100

Note 5 - Summary of Significa_3

Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Anti-dilutive securities (in shares)	7,559,032	8,100,661
Share-Based Payment Arrangement [Member]
Anti-dilutive securities (in shares)	2,444,136	2,385,871
Restricted Stock Units (RSUs) [Member]
Anti-dilutive securities (in shares)	5,395	4,600
Warrant [Member]
Anti-dilutive securities (in shares)	5,109,501	5,710,190

Note 6 - Stockholders' Equity_2

Note 6 - Stockholders' Equity (Details Textual) $ in Millions	Mar. 31, 2022USD ($)
Cancer Prevention Pharmaceuticals, Inc. [Member] | Stock and Future Milestone Achievement [Member]
Business Combination, Contingent Consideration, Liability, Total	$ 60

Note 6 - Stockholders' Equity -

Note 6 - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)	Mar. 31, 2022shares
Shares reserved (in shares)	9,578,808
Warrant [Member]
Shares reserved (in shares)	5,109,501
Share-Based Payment Arrangement, Option [Member]
Shares reserved (in shares)	2,444,136
Restricted Stock Units (RSUs) [Member]
Shares reserved (in shares)	5,395
Shares Available for Grant Under Equity Incentive Plan [Member]
Shares reserved (in shares)	2,019,776

Note 7 - Stock-based Compensa_3

Note 7 - Stock-based Compensation (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	2,444,136	2,463,636
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 1.5
Panbela Therapeutics, Inc. 2016 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	2,220,136
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	2,019,776
Panbela Therapeutics, Inc. 2016 Omnibus Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)	5,395
Panbela Therapeutics, Inc. 2011 Stock Option Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	224,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	2 years 8 months 12 days

Note 7 - Stock-based Compensa_4

Note 7 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based compensation expense	$ 334	$ 252
General and Administrative Expense [Member]
Share-based compensation expense	271	225
Research and Development Expense [Member]
Share-based compensation expense	$ 63	$ 27

Note 7 - Stock-based Compensa_5

Note 7 - Stock-based Compensation - Summary of Option Activity (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Balance, shares available for grant (in shares)	2,463,636
Balance, weighted average exercise price per share (in dollars per share)	$ 5.76
Aggregate intrinsic value	$ 13,300	$ 8,821
Granted, shares available for grant (in shares)	0
Excercised, shares available for grant (in shares)	0
Cancelled, shares available for grant (in shares)	0
Forfeitures or expirations (in shares)	(19,500)
Forfeitures or expirations (in dollars per share)	$ 14.07
Balance, shares available for grant (in shares)	2,444,136
Balance, weighted average exercise price per share (in dollars per share)	$ 5.76

Note 7 - Stock-based Compensa_6

Note 7 - Stock-based Compensation - Options Outstanding (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Options outstanding (in shares) | shares	2,444,136
Options outstanding, weighted average remaining contractual life (Year)	7 years 29 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.760
Options exercisable (in shares) | shares	1,852,268
Options excercisable, weighted average remaining contractual life (Year)	6 years 3 months 3 days
Exercise Price Range 1 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 1.10
Options outstanding (in shares) | shares	14,000
Options outstanding, weighted average remaining contractual life (Year)	1 year 2 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.100
Options exercisable (in shares) | shares	14,000
Options excercisable, weighted average remaining contractual life (Year)	1 year 2 months 12 days
Exercise Price Range 2 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.26
Options outstanding (in shares) | shares	79,225
Options outstanding, weighted average remaining contractual life (Year)	7 years 4 months 13 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.310
Options exercisable (in shares) | shares	22,000
Options excercisable, weighted average remaining contractual life (Year)	1 year 11 months 12 days
Per share exercise price, upper limit (in dollars per share)	$ 2.50
Exercise Price Range 3 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.95
Options outstanding (in shares) | shares	1,207,940
Options outstanding, weighted average remaining contractual life (Year)	7 years 2 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.410
Options exercisable (in shares) | shares	856,821
Options excercisable, weighted average remaining contractual life (Year)	6 years 7 months 13 days
Per share exercise price, upper limit (in dollars per share)	$ 4.17
Exercise Price Range 4 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 4.50
Options outstanding (in shares) | shares	687,100
Options outstanding, weighted average remaining contractual life (Year)	6 years 5 months 8 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.134
Options exercisable (in shares) | shares	609,600
Options excercisable, weighted average remaining contractual life (Year)	6 years 2 months 19 days
Per share exercise price, upper limit (in dollars per share)	$ 8.10
Exercise Price Range 5 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 9.99
Options outstanding (in shares) | shares	262,048
Options outstanding, weighted average remaining contractual life (Year)	7 years 9 months 18 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 9.992
Options exercisable (in shares) | shares	156,024
Options excercisable, weighted average remaining contractual life (Year)	7 years 5 months 19 days
Per share exercise price, upper limit (in dollars per share)	$ 10.10
Exercise Price Range 6 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 15.10
Options outstanding (in shares) | shares	193,823
Options outstanding, weighted average remaining contractual life (Year)	4 years 8 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 15.100
Options exercisable (in shares) | shares	193,823
Options excercisable, weighted average remaining contractual life (Year)	4 years 8 months 12 days